Arrowhead Pharmaceuticals Q2 2024 Earnings Report

Arrowhead Pharmaceuticals reported second quarter results for fiscal year 2024.

Key Takeaways

Arrowhead Pharmaceuticals reported a net loss of $125.3 million, or $1.02 per share, for the second quarter of fiscal year 2024. The company's revenue was $0, compared to $146.3 million in the same quarter last year. They received a $50 million milestone payment from Royalty Pharma plc in the third quarter of fiscal 2024.

Received a $50 million milestone payment from Royalty Pharma plc following the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran.

Presented final data from the Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe hypertriglyceridemia.

Initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS).

Dosed the first subjects in Phase 1/2a clinical trials of ARO-CFB and ARO-DM1.